MedTrace Logo

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

NCT04789486 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-14

No results posted yet for this study

Summary

This research study is being done to help determine the safety and efficacy of gadolinium based nanoparticle, Activation and Guidance of Irradiation X (AGuIX), used in conjunction with MR-guided stereotactic body radiation therapy (SBRT) in the treatment of pancreatic cancer and lung tumors.

Conditions

  • Non-small Cell Lung Cancer
  • Advanced Pancreatic Adenocarcinoma
  • Unresectable Pancreatic Cancer
  • Ductal Adenocarcinoma of the Pancreas

Interventions

DRUG

AGuIX

Injected gadolinium-based nanoparticles

RADIATION

Radiotherapy

Stereotactic magnetic resonance-guided adaptive radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Jonathan Leeman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-27
Primary Completion
2028-04-10
Completion
2030-04-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04789486 on ClinicalTrials.gov